Follicular Lymphoma Clinical Trials

A listing of 56 Follicular Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Follicular Lymphoma

1 - 12 of 56

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 56 active clinical trials seeking participants for Follicular Lymphoma research studies. The states with the highest number of trials for Autism participants are Texas, California, New York and Florida.

Featured Trial

Major Depressive Disorder Clinical Study

Recruiting

Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.

Conditions:

Major Depressive Disorder

Major Depression

Major Depressive Episode

Major Depressive Disorder (MDD)

Major Depressive Disorders

Learn More

Featured Trial

Hyperacusis Activities Treatment-Online Study

Recruiting

Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.

Conditions:

Hyperacusis

Tinnitus

Hearing Loss

Learn More

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT06131801

Recruiting

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown. Primary Objectives • To determ... Read More

Gender:

All

Ages:

Between 0 years and 38 years

Trial Updated:

01/24/2024

Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma

Learn More ›

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319

Recruiting

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: CD79b-19 CAR T cells Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Gender:

All

Ages:

18 years and above

Trial Updated:

04/26/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Grade 3b Follicular Lymphoma, Mantle Cell Lymphoma

Learn More ›

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

NCT06112847

Recruiting

This phase II trial tests how well lenalidomide and epcoritamab works in treating patients with follicular lymphoma that has not been previously treated. Although follicular lymphoma is incurable, prognosis has improved for both early and advanced stage disease, largely attributed to therapeutic advances. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing and by preventing the growth of new blood vessels that cancer cells need to grow. E... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/24/2024

Locations: City of Hope Medical Center, Duarte, California +1 locations

Conditions: Follicular Lymphoma

Learn More ›

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

NCT04998669

Recruiting

The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/24/2024

Locations: University of Miami, Miami, Florida

Conditions: Follicular Lymphoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297

Recruiting

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. Cohort A: Participants with relapsed or refractory MCL rel... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/19/2024

Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +101 locations

Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska

Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona

University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008, Aurora, Colorado

Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois

University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics (, Fairway, Kansas

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland

Tufts Medical Center ( Site 0024), Boston, Massachusetts

Massachusetts General Hospital ( Site 0018), Boston, Massachusetts

Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts

University of Michigan ( Site 0009), Ann Arbor, Michigan

Henry Ford Hospital ( Site 0035), Detroit, Michigan

Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio

Avera Cancer Institute- Research ( Site 0011), Sioux Falls, South Dakota

Medical Oncology Associates, PS ( Site 0005), Spokane, Washington

University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin

MEDICAL COLLEGE OF WISCONSIN ( Site 0021), Milwaukee, Wisconsin

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Rio Grande Do Norte

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), São Paulo, Sao Paulo

Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 (, Rio de Janeiro, Not set

Hospital Paulistano-Americas Oncologia ( Site 1805), Sao Paulo, Not set

BC Cancer Vancouver-Clinical Trials Unit ( Site 0201), Vancouver, British Columbia

The Moncton Hospital-Oncology ( Site 0211), Moncton, New Brunswick

QEII Health Sciences Centre - Victoria General Site ( Site 0213), Halifax, Nova Scotia

Lawson Health Research Institute - London Health Sciences Ce-London Regional Cancer Program ( Site 0, London, Ontario

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Jewish General Hospital ( Site 0202), Montreal, Quebec

Allan Blair Cancer Centre-Care Services ( Site 0208), Regina, Saskatchewan

IC La Serena Research ( Site 1909), La Serena, Coquimbo

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago, Region M. De Santiago

Clínica Alemana de Santiago ( Site 1903), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 1200), Beijing, Beijing

Sun Yat-sen University Cancer Center ( Site 1201), Guangzhou, Guangdong

Zhujiang Hospital ( Site 1207), Guangzhou, Guangdong

Southern Medical University Nanfang Hospital ( Site 1202), Guangzhou, Guangdong

Henan Cancer Hospital-hematology department ( Site 1212), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1210), Wuhan, Hubei

Tongji Hospital Tongji Medical,Science & Technology ( Site 1221), Wuhan, Hubei

The First Affiliated Hospital of Soochow University-hematology department ( Site 1218), Suzhou, Jiangsu

The Affiliated Hospital of Xuzhou Medical College ( Site 1223), Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University ( Site 1204), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 1213), Nanchang, Jiangxi

Jilin Province Tumor Hospital-oncology department ( Site 1220), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 1208), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 1206), Cheng Du, Sichuan

The First Affiliated Hospital, Zhejiang University ( Site 1211), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 1214), Hangzhou, Zhejiang

Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0300), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Klinika Hematoonkologie ( Site 0301), Ostrava, Moravskoslezsky Kraj

Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set

North Estonia Medical Centre Foundation ( Site 0401), Tallinn, Harjumaa

Universitaetsklinikum Ulm ( Site 0502), Ulm, Baden-Wurttemberg

Universitaetsklinikum Koeln ( Site 0506), Köln, Nordrhein-Westfalen

St. James's Hospital ( Site 0600), Dublin, Not set

Emek Medical Center-Hematology Unit ( Site 0705), Afula, Not set

Soroka Medical Center-Hematology Department ( Site 0707), Be'er Sheva, Not set

Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 0706), Haifa, Not set

Carmel Hospital ( Site 0709), Haifa, Not set

Hadassah Medical Center ( Site 0701), Jerusalem, Not set

Sheba Medical Center-Hemato Oncology ( Site 0700), Ramat Gan, Not set

IRCCS - AOU di Bologna-SSD: Diagnosi e terapie dei linfomi e delle sindromi linfoproliferative cron, Bologna, Emilia-Romagna

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 0804), Roma, Lazio

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0802), Rozzano, Milano

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant, Alessandria, Not set

National Hospital Organization Nagoya Medical Center ( Site 1108), Nagoya, Aichi

Hokkaido University Hospital ( Site 1104), Sapporo, Hokkaido

Tokai University Hospital- Isehara Campus ( Site 1100), Isehara, Kanagawa

Tohoku University Hospital ( Site 1106), Sendai-shi, Miyagi

Kindai University Hospital- Osakasayama Campus ( Site 1102), Osaka-sayama, Osaka

National Cancer Center Hospital ( Site 1103), Chuo-ku, Tokyo

Japanese Foundation for Cancer Research ( Site 1101), Koto, Tokyo

Kyushu University Hospital ( Site 1105), Fukuoka, Not set

Okayama University Hospital ( Site 1107), Okayama, Not set

Seoul National University Hospital ( Site 1300), Seoul, Not set

Samsung Medical Center ( Site 1301), Seoul, Not set

INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 1700), Lima, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 1008), Łódź, Lodzkie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologiczny ( Site 1006), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1001), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S, Warszawa, Mazowieckie

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Sit, Olsztyn, Warminsko-mazurskie

Champalimaud Foundation ( Site 2002), Lisbon, Lisboa

2CA BRAGA ( Site 2001), Braga, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2000), Porto, Not set

National Cancer Centre Singapore ( Site 1500), Singapore, Central Singapore

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4003), L'Hospitalet Del Llobregat, Barcelona

Clinica Universidad de Navarra ( Site 4005), Pamplona, Navarra

Hospital Universitari Vall d'Hebron ( Site 4004), Barcelona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( S, Salamanca, Not set

Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset ( Site 5003), Gothenburg, Vastra Gotalands Lan

Mega Medipol-Hematology ( Site 6009), Stanbul, Istanbul

Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 6001), Ankara, Not set

Trakya University ( Site 6005), Edirne, Not set

Ege Universitesi Hastanesi ( Site 6002), İzmir, Not set

Ondokuz Mayıs Universitesi-Oncology department ( Site 6004), Samsun, Not set

The Royal Cornwall Hospital-Haematology ( Site 7006), Truro, Cornwall

University College London Hospital ( Site 7001), London, England

The Churchill Hospital ( Site 7002), Oxford, Oxfordshire

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

Learn More ›

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT04223765

Recruiting

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on cancer cells. For this study, the anti-kappa light chain antibody has been changed so instead of floating free in the blood, a part of it is now joined to the T cells. Only the part of the antibody that sticks to the lymphoma cells is attached to the T cells. When an antibody is joined to a T cell in this way, it is called a chimeric receptor. The kappa light chain chimeric (combination) receptor-activated T cells are called ATLCAR.κ.28 cells. These cells may be able to destroy lymphoma cancer cells. They do not, however, last very long in the body so their chances of fighting the cancer are unknown. Previous studies have shown that a new gene can be put into T cells to increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying your genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells in this study makes an antibody called an anti-kappa light chain. This anti-kappa light chain antibody usually floats around in the blood. The antibody can detect and stick to cancer cells called lymphoma cells because they have a substance on the outside of the cells called kappa light chains. The purpose of this study is to determine whether receiving the ATLCAR.κ.28 cells is safe and tolerable and learn more about the side effects and how effective these cells are in fighting lymphoma. Initially, the study doctors will test different doses of the ATLCAR.κ.28, to see which dose is safer for use in lymphoma patients. Once a safe dose is identified, the study team will administer this dose to more patients, to learn about how these cells affect lymphoma cancer cells and identify other side effects they might have on the body. This is the first time ATLCAR.κ.28 cells are given to patients with lymphoma. The Food and Drug Administration (FDA), has not approved giving ATLCAR.κ.28 as treatment for lymphoma. This is the first step in determining whether giving ATLCAR.κ.28 to others with lymphoma in the future will help them. Read Less

Gender:

All

Ages:

18 years and above

Trial Updated:

04/19/2024

Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma

Learn More ›

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

NCT06350318

Recruiting

The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

Gender:

All

Ages:

18 years and above

Trial Updated:

04/19/2024

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma

Learn More ›

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma

NCT04224493

Recruiting

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after treatment and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/18/2024

Locations: Southern Cancer Center, Mobile, Alabama +161 locations

Southern Cancer Center, Mobile, Alabama

Arizona Oncology Associates - Tuscon-Rusadill Road, Tucson, Arizona

TOI - Clinical Research, Cerritos, California

UCSF Fresno, Clovis, California

UC San Diego Health Sciences, La Jolla, California

UCLA Clinical Research Unit Hematology/Oncology, Santa Monica, California

Rocky Mountain Cancer Centers (RMCC) - Boulder, Boulder, Colorado

St. Mary's Hospital and Regional Medical Center - St. Mary's, Grand Junction, Colorado

SCL Health Lutheran Medical Center, Greeley, Colorado

Cancer Specialists of North Florida, Fleming Island, Florida

Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center, Fort Myers, Florida

Mayo Clinic - Cancer Clinical Research Office, Jacksonville, Florida

Mayo Clinic, Jacksonville, Florida

Miami Cancer Institute, Miami, Florida

Florida Cancer Affiliates/Ocala Oncology - Clinic, Ocala, Florida

BRCR Medical Center, INC, Plantation, Florida

Florida Cancer Specialists, Saint Petersburg, Florida

Florida Cancer Specialists - Panhandle, Tallahassee, Florida

H Lee Moffitt Cancer Center and Research Institute I, Tampa, Florida

Florida Cancer Specialists & Research Institute (FCS) - Atlantis, West Palm Beach, Florida

Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii

University of Chicago, Chicago, Illinois

Illinois Cancer Specialists, Niles, Illinois

June E. Nylen Cancer Center, Sioux City, Iowa

The University of Kansas Cancer Center, Overland Park, Kansas

University of Maryland, Baltimore, Maryland

The office of Frederick P. Smith, MD, P.C., Chevy Chase, Maryland

Mass General Cancer Center at Newton-Wellesley, Newton, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

St. Joseph Mercy Hospital, Ypsilanti, Michigan

Mayo Clinic - Rochester, Rochester, Minnesota

Saint Louis University Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Astera Cancer Care, East Brunswick, New Jersey

Astera Cancer Center, East Brunswick, New Jersey

Regional Cancer Care Associates-Freehold, Freehold, New Jersey

Hackensack University Medical John Theurer Cancer Center, Hackensack, New Jersey

Regional Cancer Care Associates LLC - Howell, Howell, New Jersey

Regional Cancer Care Associates LLC - Little Silver, Little Silver, New Jersey

New Mexico Cancer Care Alliance, Albuquerque, New Mexico

New York Oncology Hematology, P.C., Albany, New York

Northwell Health/Monter Cancer Center, Lake Success, New York

Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York

Columbia U - Herbert Irving Comprehensive Cancer Center, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Hematology Oncology Associates of Rockland, P.C., Nyack, New York

Messino Cancer Center, Asheville, North Carolina

Levine Cancer Institute - Concord, Concord, North Carolina

FirstHealth of the Carolinas, Pinehurst, North Carolina

Gabrail Cancer Center Research, Canton, Ohio

Oncology Hematology Care (OHC), Inc. - Kenwood Office, Cincinnati, Ohio

Willamette Valley Cancer Institute and Research Center - Oncology, Eugene, Oregon

University of Pittsburgh Medical Center - Oncology, Pittsburgh, Pennsylvania

Western Pennsylvania Hospital Hematology & Cellular Therapy, Pittsburgh, Pennsylvania

Tennessee Oncology, PLLC, Chattanooga, Tennessee

University of Tennessee Medical Center - Cancer Institute, Knoxville, Tennessee

Sarah Cannon Research Institute, Nashville, Tennessee

Texas Oncology - Amarillo, Amarillo, Texas

Texas Oncology-Austin Midtown, Austin, Texas

Texas Oncology - Medical City Dallas Pediatric Hematology, Dallas, Texas

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Millennium Physicians - Oncology, Houston, Texas

Texas Oncology, Plano, Texas

Mays Cancer Center, San Antonio, Texas

UT Health East Texas HOPE Cancer Center - Tyler, Tyler, Texas

USO Texas Oncology - Tyler, Tyler, Texas

Texas Oncology- Weslaco, Weslaco, Texas

Utah Cancer Specialists/ IHO Corp, Salt Lake City, Utah

Huntsman Cancer Institute; The University of Utah, Salt Lake City, Utah

Peninsula Cancer Institute, Chesapeake, Virginia

Virginia Cancer Specialists, Gainesville, Virginia

Oncology and Hematology Associates of Southwest Virginia Inc., Roanoke, Virginia

MC Rockwood Cancer Bl Specialty Ctr - North, Spokane, Washington

Yakima Valley Memorial Hospital - North Star Lodge Cancer Center, Yakima, Washington

Royal Adelaide Hospital, Adelaide, South Australia

Flinders Medical Centre, Bedford Park, South Australia

Monash Health, Clayton, Victoria

Barwon Health, University Hospital Geelong, Geelong, Victoria

Hollywood Private Hospital, Nedlands, Western Australia

CHU Dinant Godinne UCL Namur, Yvoir, Namur

Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen

UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant

University Health Network Princess Margaret Hospital, Toronto, Ontario

Centre Hospitalier de l'Universite de Montreal (CHUM), Montréal, Quebec

Sir Mortimer B Davis/Jewish General Hospital, Montréal, Quebec

Fujian Medical University Union Hospital, Fuzhou, Fujian

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian

The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou

The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, Hangzhou

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei

Henan Provincial People's Hospital, Zhengzhou, Henan

Henan Cancer Hospital, Zhengzhou, Henan

Hunan Cancer Hospital, Changsha, Hunan

The First Bethune Hospital of Jilin University, Changchun, Jinlin

The Affiliated Hospital of Qingdao University, Qingdao, Shandong

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai

Shanxi Bethune Hospital, Taiyuan, Shanxi

Peking University Third Hospital, Beijing, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set

Centre Hospitalier Universitaire de Bordeaux-Hopital du Haut Leveque, Pessac Cedex, Aquitaine

CHRU Brest Hôp Morvan, Brest, Bretagne

Institut Bergonie, Bordeaux, Gironde

Centre Hosp Mulh Hop Emile Muller, Mulhouse, Haut-Rhin

Centre Henri Becquerel, Rouen, Haute-Normandie

CHU de Limoges Dupuytren, Limoges, Haute-Vienne

CHU de Grenoble - Hopital Albe, La Tronche, Isere

CHU de Nantes - Hematologie, Nantes, Loire-Atlantique

CHRU de Lille Hop Claude Huriez, Lille, Nord

Centre Hospitalier Le Mans, Le Mans, Sarthe

CHRU de Besançon- Hopital Jean Minjoz, Besancon, Not set

CHU Caen, Caen, Not set

CHU de Clermont-Ferrand, site Estaing, Clermont-Ferrand, Not set

L'Hôpital Privé Confluent, Nantes, Not set

Hopital Saint Louis, Paris, Not set

CHU de Nancy Brabois, Vandœuvre-lès-Nancy, Not set

Centre Hospitalier Bretagne Atlantique, Vannes, Not set

Hopital Henri Mondor - Hemopathies Lymphoides, Créteil, Île-de-France

Diakoneo Diak Schwaebisch Hall gGmbH, Schwäbisch Hall, Baden-Württemberg

Klinikum Der Universität München AöR, München, Bayern

Klinikum rechts der Isar der Technischen Universitat Muenche, München, Bayern

Universitätsmedizin Mainz, Mainz, Hessen

Universitaetsklinikum Bonn AöR, Bonn, Nordrhein-Westfalen

Kliniken Maria Hilf GmbH, Moenchengladbach, Nordrhein-Westfalen

Städt. Krankenhaus Kiel, Kiel, Schleswig-Holstein

Debreceni Egyetem Klinikai Központ, Debrecen, Hajdú-Bihar

Semmelweis Egyetem Általános Orvostudományi Kar, Budapest, Not set

Országos Onkológiai Intézet, Budapest, Not set

Del-pesti Centrumkorhaz Orszagos Hematologiai és Infektologiai Intezet, Budapest, Not set

AOU Federico II, Napoli, Campania

Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS, Meldola, Forli-Cesena

ASST Spedali Civili di Brescia, Brescia, Not set

PO Garibaldi-Nesima, ARNAS Garibaldi, Catania, Not set

AOU Careggi, Firenze, Not set

Catholic University Of Sacred Heart, Roma, Not set

Azienda Ospedaliera Santa Maria di Terni, Terni, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp]

Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Mazowieckie

Centrum Medyczne Pratia Poznan, Skorzewo, Wielkopolskie

Pratia Onkologia Katowice, Katowice, Not set

Pratia MCM Krakow, Kraków, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., Słupsk, Not set

MICS Centrum Medyczne Torun, Torun, Not set

Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Not set

Hospital Universitari Vall d'Hebrón, Barcelona, Cataluny

Hospital Costa del Sol, Marbella, Málaga

Hospital Del Mar, Barcelona, Not set

Hospital Univ. Infanta Leonor, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Nuestra Señora de Valme, Sevilla, Not set

Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology, Kaohsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Western General Hospital - Haematology, Edinburgh, Edinburgh, City Of

Imperial College Healthcare NHS Trust - Hammersmith Hospital, London, London City

St Bartholomew's Hospital Barts Health NHS Trust, London, London, City Of

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

Learn More ›

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974

Recruiting

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Gender:

All

Ages:

60 years and below

Trial Updated:

04/15/2024

Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes

Learn More ›

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

NCT06004167

Recruiting

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This i... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/12/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations

Conditions: Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma

Learn More ›

Clonal Evolution in Follicular Lymphoma

NCT03190928

Recruiting

Background: Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future treatments. Objective: To collect a variety of samples from people with follicular lymphoma to study how these diseases progress and respond to treatment. Eligibili... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/12/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Follicular Lymphoma

Learn More ›

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

NCT05565417

Recruiting

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: Find the recommended dose of IMT-009 that can be safely given to participants Learn more about the side effects of IMT-009 Learn more about pharmacokinetics of IMT-009 Learn more about the effectiveness of IMT-009 Learn more about different pharmacokinetic b... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/09/2024

Locations: Site 9618, Tucson, Arizona +9 locations

Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma

Learn More ›

1 - 12 of 56